Hyper IgE syndrome: An update on clinical aspects and the role of signal transducer and activator of transcription 3

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 6, 2008, Pages 527-533

  Paulson, Michelle L ^a   Freeman, Alexandra F ^b   Holland, Steven M ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c MSC 1684 ^*  (United States)

Author keywords

Hyper IgE syndrome; Job's syndrome; Recurrent infections; Signal transducer and activator of transcription 3; Th17 cells

Indexed keywords

ANTIINFECTIVE AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL PNEUMONIA; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CONGENITAL BLOOD VESSEL MALFORMATION; CRANIOFACIAL MALFORMATION; CYTOKINE PRODUCTION; GENE MUTATION; GENETIC ANALYSIS; HELPER CELL; HUMAN; HYPER IGE SYNDROME; IMMUNE RESPONSE; IMMUNOGENETICS; INFECTION; INFECTION PREVENTION; LABORATORY TEST; MALIGNANT NEOPLASTIC DISEASE; MUCOCUTANEOUS CANDIDIASIS; MUSCULOSKELETAL SYSTEM MALFORMATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TOOTH MALFORMATION;

ADULT; AGE FACTORS; ANIMALS; CORONARY ARTERY DISEASE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT, NEWBORN; INFECTION; JANUS KINASES; JOB'S SYNDROME; MICE; MUTATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 56749174754     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283184210     Document Type: Review

References (62)

1. Davis SD, Scaller SJ, Wedgwood RJ. Job's syndrome: recurrent, 'cold', staphylococcal abscesses. Lancet 1966; 1:1013-1015.
2. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972; 49:59-70.
3. Buckley RH. The hyper-lgE syndrome. Clin Rev Allergy Immunol 2001; 20:139-154.
4. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. N Engl J Med 1999; 340:692-702.
5. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-lgE syndrome. N Engl J Med 2007; 357:1608-1619. This study describes 18 mutations in STAT3 from families and individuals with HIES in both the DNA-binding and SH2 domains. They show elevated expression of proinflammatory genes by microarray and increased proinflammatory cytokine responses from stimulated leukocytes.
6. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-lgE syndrome. Nature 2007; 448:1058-1062. This study describes five HIES-causing mutations within the DNA-binding domain of STAT3. They show that the mutations alone are nonfunctional and produce a dominant-negative interaction with wild-type STAT3, as well as interference with IL-6 and IL-10 signaling.
7. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced Th17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008; 122:181-187. This study reports novel mutations in STAT3 that lead to HIES syndrome and validates defective Th17 cell production in HIES.
8. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205:1543-1550. This study reports new mutations of STAT3 in HIES patients and demonstrates diminished Th17 cell production in HIES.
9. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008; 205:1551-1557. This study lists new mutations in STAT3 leading to HIES and additionally shows reduced Th17 cell production and decreased IL-22 expression.
10. Jiao H, Toth B, Erdos M, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol 2008 [Epub ahead of print]. This study reports a novel mutation in STAT3 causing HIES in exon 9 of the DNA-binding domain.
11. Chamlin SL, McCalmont TH, Cunningham BB, et al. Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 2002; 141:572-575.
12. Eberting CL, Davis J, Puck JM, Holland SM. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 2004; 140:1119-1125.
13. Freeman AF, Kleiner DE, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007; 119:1234-1240.
14. Hutto JO, Bryan CS, Greene FL, et al. Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E syndrome. Gastroenterology 1988; 94:808-812.
15. Jacobs DH, Macher AM, Handler R, et al. Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome. Gastroenterology 1984; 87:201-203.
16. Freeman AF, Davis J, Anderson VL, et al. Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 2006; 118:e1271-e1275.
17. Freeman AF, Collura-Burke CJ, Patronas NJ, et al. Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 2007; 119:e1121-e1125.
18. Hoger PH, Boltshauser E, Hitzig WH. Craniosynostosis in hyper-IgE syndrome. Eur J Pediatr 1985; 144:414-417.
19. Smithwick EM, Finelt M, Pahwa S, et al. Cranial synostosis in Job's syndrome. Lancet 1978; 15:826.
20. Cohen-Solal M, Prieur AM, Prin L, et al. Cytokine-mediated bone resorption in patients with the hyperimmunoglobulin E syndrome. Clin Immunol Immunopathol 1995; 76:75-81.
21. Leung DY, Key L, Steinberg JJ, et al. Increased in vitro bone resorption by monocytes in the hyper-immunologulin E syndrome. J Immunol 1988; 140:84-88.
22. O'Connell AC, Puck JM, Grimbacher B, et al. Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89:177-185.
23. Domingo DL, Freeman AF, Davis J, et al. Novel intraoral phenotypes in hyperimmunoglobulin-E syndrome. Oral Dis 2008; 14:73-81.
24. Ling JC, Freeman AF, Gharib AM, et al. Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol 2007; 122:255-258.
25. Young TY, Jerome D, Gupta S. Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells. Ann Allergy Asthma Immunol 2007; 98:389-392.
26. Leonard GD, Posadas E, Herrmann PC, et al. Non-Hodgkin's lymphoma in Job's syndrome: a case report and review of the literature. Leuk Lymphoma 2004; 45:2521-2525.
27. Oztop I, Demirkan B, Tarhan O, et al. The development of a pulmonary adenocarcinoma in a patient with Job's syndrome, a rare immunodeficiency condition. Tumori 2004; 90:132-135.
28. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282:20059-20063.
29. Levy DE, Loomis CA. STAT3 signaling and the hyper-IgE syndrome. N Engl J Med 2007; 357:1655-1658.
30. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:2623-2629.
31. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94:3801-3804.
32. Hokuto I, Ikegami M, Yoshida M, et al. Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 2004; 113:28-37.
33. Zhang A, Weite T, Troiano N, et al. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Commun 2005; 328:800-807.
34. Welte T, Zhang SSM, Wang T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003; 100:1879-1884.
35. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999; 18:4657-4668.
36. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 2006; 12:829-834.
37. Levy DE, Lee C. What does Stat3 do? J Clin Invest 2002; 109:1143-1148.
38. Hill HR, Ochs HD, Quie PG, et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent 'cold' staphylococcal abscesses. Lancet 1974; 14:617-619.
39. Tanaka T, Takada H, Nomura A, et al. Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome. Clin Exp Immunol 2005; 140:524-531.
40. Netea MG, Kullberg BJ, van der Meer JWM. Severely impaired IL-12/IL-18/IFNγ axis in patients with hyper IgE syndrome. Eur J Clin Invest 2005; 35:718-721.
41. Chehimi J, Elder M, Greene J, et al. Cytokine and chemokine dysregulation in hyper-IgE syndrome. Clin Immunol 2001; 100:49-56.
42. Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent-infection (Job's syndrome). A review of the NIH experience and the literature. Medicine 1983; 62:195-208.
43. Borges WG, Augustine NH, Hill HR. Defective interleukin-12/interferon- gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 2000; 136:176-180.
44. Del Prete G, Tiri A, Maggi E, et al. Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome. J Clin Invest 1989; 84:1830-1835.
45. Renner ED, Pawlita I, Hoffmann F, et al. No indication for a defect in Toll-like receptor signaling in patients with Hyper-IgE syndrome. J Clin Immunol 2005; 321-328.
46. Murray PJ. STAT3-mediated anti-inflammatory signaling. Biochem Soc Trans 2006; 34:1028-1031.
47. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10:39-49.
48. Dong C. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8:337-348. An excellent overview of Th17 cell function, differentiation and regulation.
49. Harris TJ, Grosso JF, Yen HR, et al. An in vivo requirement for STAT3 signaling in Th17 development and Th17-dependent autoimmunity. J Immunol 2007; 179:4313-4317.
50. Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358-9363.
51. Milner JD, Brenchley JM, Laurence A, et al. Impaired Th17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776. This is the first study to demonstrate that HIES patients lack IL-17-producing T cells and that their T cells are unable to be differentiated to produce Th17 cells in vitro.
52. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-631.
53. Aujla SH, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 2008; 14:275-281.
54. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-254.
55. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-1160.
56. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298:1630-1634.
57. Avery DT, Ma CS, Bryant VL, et al. STAT3 is required for IL-21-induced secretion of IgE from human naïve B cells. Blood 2008; 112:1784-1793.
58. Kimata H. High-dose intravenous γ-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1995; 95:771-774.
59. Wakim M, Alazard M, Yajima A, et al. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998; 81:153-158.
60. Bilora F, Petrobelli F, Bocioletti V, Pomerri F. Moderate-dose intravenous immunoglobulin treatment of Job's syndrome. Case report. Minerva Med 2000; 91:113-116.
61. Nester TA, Wagnon AH, Reilly WF, et al. Effects of allogeneic peripheral stem cell transplantation in a patient with Job syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med 1998; 105:162-164.
62. Gennery AR, Flood TJ, Abinun M, Cant AJ. Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant 2000; 25:1303-1305.